Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab-based combinations after prior immunochemotherapy failure in extensive-stage small cell lung cancer
ChiCTR2300078968Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab, Rivoceranib and paclitaxel in small cell lung cancer (SCLC) (3 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimabRivoceranibpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300078968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078968.